𝔖 Bobbio Scriptorium
✦   LIBER   ✦

992 Human phase II/A study of a novel somatostatin analogue, TT-232 in malignant melanoma patients

✍ Scribed by F. Gyergyay; M. Gödény; T. Szüts; Gy. Kéri; G. Sármay; I. Bodrogi

Book ID
118621156
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
170 KB
Volume
1
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of spirogermanium in pa
A phase II study of spirogermanium in patients with metastatic malignant melanoma
✍ Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; K 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 205 KB

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc

A phase II study of autologous irradiate
A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma
✍ J. Frederick Laucius; Audley J. Bodurtha; Michael J. Mastrangelo; Robert E. Bell 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Eighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumors cells (1-2 X 10(8)) and BCG (Glaxo, 2-4.5 X 10(6) organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (2